Zydus Lifesciences Ltd Share Price (ZYDUSLIFE)

Zydus Lifesciences Stock Up by 33% - 18 Apr, 2024

Zydus Lifesciences stock has seen a significant increase of 33% over the last three months. The company's financial indicators, particularly ROE, were studied to see if they played a role in this price move.

Zydus Lifesciences Receives WHO Approval for Usnoflast - 01 Apr, 2024

Zydus Lifesciences has received approval from the WHO International Non-proprietary Names (INN) for Usnoflast as the recommended name for ZYIL1, a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated its efficacy in pre-clinical models of neuroinflammation, Parkinson's disease, IBD, and MS. Phase I studies found it to be safe and well-tolerated.

Zydus Lifesciences Non-Executive Chairman Sells Shares Worth ₹588m - 31 Mar, 2024

Non-Executive Chairman Pankaj Patel sold Zydus Lifesciences shares worth ₹588m at a price of ₹1,009 per share. While insider selling is not positive, the sale took place around the current price and only reduced their holding by 0.08%. Insiders haven't been buying, but the company's growing earnings are promising. However, it's important to note that the company has high debt levels.

Zydus Lifesciences Reports Strong Q3 Results Despite USFDA Observations - 28 Mar, 2024

Zydus Lifesciences reported a strong Q3 FY24 performance despite the USFDA issuing four observations following an inspection of its SEZ Onco Injectable manufacturing plant in Ahmedabad. The company's consolidated net profit increased by 26.76% to Rs 789.6 crore, while revenue rose 5.83% to Rs 4,343.70 crore. Shares traded volatile on D-Street.

Zydus Life Receives USFDA Approval and Announces Share Buyback - 23 Mar, 2024

Zydus Lifesciences has received tentative approval from the USFDA to market Letermovir tablets and two injections. Additionally, the company announced a share buyback of equity shares and introduced Olaparib in India under the brand IBYRA. Zydus is focusing on NCE research and aims for double-digit growth.

Zydus Lifesciences Receives Buy Rating from Sharekhan - 21 Mar, 2024

Sharekhan has reiterated a Buy rating on Zydus Lifesciences, citing strong domestic sales growth and focus on specialty products in India and the US. The company recently received approval for Finasteride and Tadalafil Capsules in the US market with 180 days of exclusivity. Sharekhan expects earnings to grow at a CAGR of 15% from FY24-26E, leading to an increase in their price target to Rs. 1100/share.